DeCure's autonomous AMR AI scientist is researching a drug-repurposing hypothesis for HIV-Associated Lipodystrophy Syndrome — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHIV-Associated Lipodystrophy Syndrome maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hiv-associated lipodystrophy syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
growth hormone releasing hormone receptor (GHRHR) — GHRHR is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet plmdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7CZ5 · 2.6 Å · ligand PALMITIC ACID (PLM). Experimental structure, not a prediction.
What the evidence adds up to
HIV-associated lipodystrophy syndrome is a collection of morphological and metabolic abnormalities linked to antiretroviral therapy and other risk factors. In children, as in adults, the condition has been linked to antiretroviral agents, but little is known about its pathophysiology, and even less about its long-term effects. In one paediatric HIV clinic, three patients who developed the syndrome were not treated specifically for it due to a lack of knowledge about its natural course and the risks versus benefits of treatment; their lipid profiles were monitored twice yearly.
Surgical interventions have been studied for the focal fat accumulation (lipohypertrophy) component of the syndrome. A 15-year retrospective review of nine male patients who underwent 17 procedures found that among five patients who had liposuction as the initial intervention, 60% (three patients) experienced a recurrence. All three cases of primary liposuction followed by excisional lipectomy also recurred postoperatively, and there was one seroma. Among four patients who underwent excisional lipectomy alone, there were no documented recurrences, though one postoperative course was complicated by seroma. The authors recommend excisional lipectomy as the primary treatment, with liposuction reserved for contouring and subsequent procedures.
Medical management has been of only limited success in many cases. Present data indicate a multifactorial pathogenesis involving HIV infection, its therapy, and patient-related factors. General recommendations include dietary changes, lifestyle modifications, and altering antiretroviral drug therapy — for example, substituting stavudine or zidovudine with abacavir or tenofovir, or replacing protease inhibitors with non-nucleoside reverse-transcriptase inhibitors — as well as the use of metabolically active drugs. The metabolic abnormalities may harbour a significant risk for cardiovascular disease with as yet unknown consequences.
What is still missing are large, prospective studies that can clarify the natural history of the syndrome, particularly in children, and randomised trials comparing medical and surgical interventions with adequate follow-up to assess both recurrence and cardiovascular outcomes. Funding for such trials and for the development of patient stratification tools that could predict who will benefit from which approach remains absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Antiviral Therapy · 2001 · 96 citations · open access
Antiretroviral Therapy and the Lipodystrophy Syndrome
Abstract'Lipodystrophy syndrome' in the setting of HIV infection has come to encompass a collection of morphological and metabolic abnormalities linked with the use of antiretroviral therapy and other risk factors. We review the clinical literature on this subject as it has evolved historically, taking pertinent methodological issues into account.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2001 · 30 citations
Lipodystrophy Syndrome in Children Infected with Human Immunodeficiency Virus
AbstractLipodystrophy syndrome (LDS), a fat-wasting condition commonly reported in adults infected with human immunodeficiency virus (HIV), has been linked to the use of antiretroviral agents. Recently, LDS was observed in children infected with HIV Little is known about the pathophysiology of this condition, although it is believed that LDS has many causes and modes of presentation. Even less is known about what long-term effects LDS will have on HIV-infected patients. Three patients who developed LDS were observed in a pediatric HIV clinic. Due to the lack of knowledge about the condition's natural course and the benefits versus risks of treatment, they were not treated specifically for LDS. Their lipid profiles, however, continue to be monitored closely twice/year.
Archives of Plastic Surgery · 2021 · 12 citations · open access
Excisional lipectomy versus liposuction in HIV-associated lipodystrophy
AbstractBACKGROUND: Human immunodeficiency virus (HIV)-associated lipodystrophy is a known consequence of long-term highly active antiretroviral therapy (HAART). However, a significant number of patients on HAART therapy were left with the stigmata of complications, including fat redistribution. Few studies have described the successful removal of focal areas of lipohypertrophy with successful outcomes. This manuscript reviews the outcomes of excisional lipectomy versus liposuction for HIV-associated cervicodorsal lipodystrophy. METHODS: We performed a 15-year retrospective review of HIV-positive patients with lipodystrophy. Patients were identified by query of secure operative logs. Data collected included demographics, medications, comorbidities, duration of HIV, surgical intervention type, pertinent laboratory values, and the amount of tissue removed. RESULTS: Nine male patients with HIV-associated lipodystrophy underwent a total of 17 procedures. Of the patients who underwent liposuction initially (n=5), 60% (n=3) experienced a recurrence. There were a total of three cases of primary liposuction followed by excisional lipectomy. One hundred percent of these cases were noted to have a recurrence postoperatively, and there was one case of seroma formation. Of the subjects who underwent excisional lipectomy (n=4), there were no documented recurrences; however, one patient's postoperative course was complicated by seroma formation. CONCLUSIONS: HIV-associated lipodystrophy is a disfiguring complication of HAART therapy with significant morbidity. Given the limitations of liposuction alone as the primary intervention, excisional lipectomy is recommended as the primary treatment. Liposuction may be used for better contouring and for subsequent procedures. While there is a slightly higher risk for complications, adjunctive techniques such as quilting sutures and placement of drains may be used in conjunction with excisional lipectomy.
Expert Opinion on Pharmacotherapy · 2007 · 7 citations
Treatment options for lipodystrophy in HIV-positive patients
AbstractThe HIV-associated lipodystrophy syndrome is one of the major side effects of HIV-therapy. Its metabolic abnormalities may harbor a significant risk for cardiovascular disease with as yet unknown consequences. Present data indicate a rather multifactorial pathogenesis where HIV infection, its therapy and patient-related factors are major contributors. Therapeutic interventions in patients with lipodystrophy have so far been of only limited success in many cases. General recommendations include dietary changes and lifestyle modifications, altering antiretroviral drug therapy (substitution of stavudine and zidovdine with e.g., abacavir or tenofovir or replacement of protease inhibitors with non-nucleoside reverse-transcriptase inhibitors), and finally, the use of metabolically active drugs. Here, the treatment options of the HIV-lipodystrophy syndrome are summarized based on the present literature.
Adverse Drug Reaction Bulletin · 2003 · 0 citations
Lipodystrophy associated with treatment of HIV-1 infection
AbstractThis review describes a lipodystrophy syndrome often seen in recent years in the treatment of HIV-1-positive patients. The syndrome consists of a redistribution in fat, hyperlipidaemia, and insulin resistance, and potentially undermines an important part of the enormous success that the introduction of potent antiretroviral therapy has gained. We describe the different aspects of the syndrome, its implications, and its potential aetiology.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
